Uncategorized
With 3 quick buyouts, Gilead leans into its latest transformation
On a conference call with analysts, Gilead walked through how a string of recent deals focused on cancer and autoimmune conditions could help a diversification plan it’s long struggled to execute.
Uncategorized
Nektar surges again as alopecia drug shows new promise in extension study

Patients who’d seen substantial hair regrowth in the first part of Nektar’s trial had a “deepening” treatment response, extending a comeback bid that’s caused shares to skyrocket over the last year.

Patients who’d seen substantial hair regrowth in the first part of Nektar’s trial had a “deepening” treatment response, extending a comeback bid that’s caused shares to skyrocket over the last year.
Uncategorized
Merck partner reveals bispecific data; Biogen pays $100M for antibody rights
Merck partner reveals bispecific data; Biogen pays $100M for antibody rights
Merck partner reveals first human data for PD-1xVEGF bispecific: Sino Biopharm revealed that six of 11 lung cancer patients responded to a low dose of the drug, known as MK-2010, while four of nine patients … Read More
Uncategorized
STAT+: The PBMs fight back, and arbitration doesn’t lose
This is the online version of STAT’s weekly email newsletter Health Care Inc. Sign up here.
Did you know it’s National Library Week? Of course you did, you look so studious. To honor the thrill of reading and learning, STAT is offering 60% off our subscription for your first year. Check it out, visit a library, and as always, say hello: bob.herman@statnews.com.
A contentious fight over drug price transparency
Anna Yeo/STAT
The phalanx of lobbyists representing pharmacy benefit managers and health insurers has mounted stiff opposition to a federal proposal that attempts to pry open the black box of prescription drug prices.
This is the online version of STAT’s weekly email newsletter Health Care Inc. Sign up here.
Did you know it’s National Library Week? Of course you did, you look so studious. To honor the thrill of reading and learning, STAT is offering 60% off our subscription for your first year. Check it out, visit a library, and as always, say hello: bob.herman@statnews.com.
A contentious fight over drug price transparency
Anna Yeo/STAT
The phalanx of lobbyists representing pharmacy benefit managers and health insurers has mounted stiff opposition to a federal proposal that attempts to pry open the black box of prescription drug prices.
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Contributors9 years agoThe final 6 ‘Game of Thrones’ episodes might feel like a full season
-
Uncategorized9 years agoAccording to Dior Couture, this taboo fashion accessory is back
-
Uncategorized9 years agoPhillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years agoUber and Lyft are finally available in all of New York State
-
Uncategorized9 years agoThe old and New Edition cast comes together to perform
-
Uncategorized9 years agoSteph Curry finally got the contract he deserves from the Warriors
-
Uncategorized9 years agoDisney’s live-action Aladdin finally finds its stars